Oric Pharmaceuticals, Inc. — Director's Dealing 2022

Mar 25, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2022-03-23

Reporting Person: Chacko Jacob (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-23	Common Stock	P	257127	$4.9815	Acquired	259779	Direct
2022-03-24	Common Stock	P	42873	$5.0302	Acquired	302652	Direct
2022-03-25	Common Stock	P	50000	$4.5434	Acquired	352652	Direct

Footnotes

F1: Represents the weighted average share price of an aggregate total of 257,127 shares purchased in the price range of $4.73 to $5.10 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Represents the weighted average share price of an aggregate total of 42,873 shares purchased in the price range of $5.03 to $5.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average share price of an aggregate total of 50,000 shares purchased in the price range of $4.455 to $4.60 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.